TG Therapeutics Balance Sheet Health
Financial Health criteria checks 4/6
TG Therapeutics has a total shareholder equity of $237.3M and total debt of $245.6M, which brings its debt-to-equity ratio to 103.5%. Its total assets and total liabilities are $656.7M and $419.4M respectively. TG Therapeutics's EBIT is $59.8M making its interest coverage ratio 2.1. It has cash and short-term investments of $276.2M.
Key information
103.51%
Debt to equity ratio
US$245.61m
Debt
| Interest coverage ratio | 2.1x |
| Cash | US$276.24m |
| Equity | US$237.29m |
| Total liabilities | US$419.40m |
| Total assets | US$656.69m |
Recent financial health updates
Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Apr 09
TG Therapeutics (NASDAQ:TGTX) Has Debt But No Earnings; Should You Worry?
Jan 07TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet
Aug 02Recent updates
TG Therapeutics' (NASDAQ:TGTX) Weak Earnings May Only Reveal A Part Of The Whole Picture
May 16Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Apr 09TG Therapeutics: Bright Outlook, Bolstered By Briumvi And Upcoming Trials
Mar 14Risks To Shareholder Returns Are Elevated At These Prices For TG Therapeutics, Inc. (NASDAQ:TGTX)
Mar 02TG Therapeutics (NASDAQ:TGTX) Has Debt But No Earnings; Should You Worry?
Jan 07Optimistic Investors Push TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Up 27% But Growth Is Lacking
Nov 07TG Therapeutics: Modest Q3 Sales Beat, Focus Shifts To Early 2025 Updates
Nov 05
BRIUMVI's Breakthrough In MS Market Promises Robust Revenue Surge And Expanding Therapeutic Horizons
Strong sales of BRIUMVI and strategic expansions such as innovative versions aim to secure market dominance in treating relapsing multiple sclerosis.TG Therapeutics, Inc.'s (NASDAQ:TGTX) Shares Bounce 27% But Its Business Still Trails The Industry
Sep 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 09TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback
Aug 07TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet
Aug 02Hold TG Therapeutics For Intriguing Outcomes
Jun 12TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement
May 29TG Therapeutics: Less Room For Doubt About Briumvi
May 03TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Jan 10Financial Position Analysis
Short Term Liabilities: TGTX's short term assets ($644.5M) exceed its short term liabilities ($160.2M).
Long Term Liabilities: TGTX's short term assets ($644.5M) exceed its long term liabilities ($259.2M).
Debt to Equity History and Analysis
Debt Level: TGTX has more cash than its total debt.
Reducing Debt: TGTX had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Debt Coverage: TGTX's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: TGTX's interest payments on its debt are not well covered by EBIT (2.1x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 10:58 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
TG Therapeutics, Inc. is covered by 19 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alec Stranahan | BofA Global Research |
| Jonathan Aschoff | Brean Capital |
| Mayank Mamtani | B. Riley Securities, Inc. |